Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia - PubMed (original) (raw)
Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia
E J Steinbart et al. Arch Neurol. 2001 Nov.
Abstract
Background: DNA testing of persons at risk for hereditary, degenerative neurologic diseases is relatively new. Only anecdotal reports of such testing in familial Alzheimer disease (FAD) exist, and little is know about the personal and social impact of such testing.
Methods: In a descriptive, observational study, individuals at 50% risk for autosomal dominant, early-onset FAD or frontotemporal dementia with parkinsonism linked to chromosome 17 underwent DNA testing for the genetic mutations previously identified in affected family members. Individuals were followed up for (1/2) to 3 years and were interviewed regarding attitudes toward the testing process and the impact of the results.
Results: Twenty-one (8.4%) of 251 persons at risk for FAD or frontotemporal dementia requested genetic testing. The most common reasons for requesting testing were concern about early symptoms of dementia, financial or family planning, and relief from anxiety. Twelve individuals had positive DNA test results, and 6 of these had early symptoms of dementia; 8 had negative results; and 1 has not yet received results. Of 14 asymptomatic individuals completing testing, 13 believed the testing was beneficial. Two persons reported moderate anxiety and 1 reported moderate depression. As expected, persons with negative test results had happier experiences overall, but even they had to deal with ongoing anxiety and depression. Thus far, there have been no psychiatric hospitalizations, suicide attempts, or denials of insurance.
Conclusions: Genetic testing in early-onset FAD and frontotemporal dementia can be completed successfully. Most individuals demonstrate effective coping skills and find the testing to be beneficial, but long-term effects remain unknown.
Similar articles
- Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia.
Signorini S, Ghidoni R, Barbiero L, Benussi L, Binetti G. Signorini S, et al. Curr Alzheimer Res. 2004 Aug;1(3):215-8. doi: 10.2174/1567205043332108. Curr Alzheimer Res. 2004. PMID: 15975068 - [Genetic counseling and testing for families with Alzheimer's disease].
Kowalska A. Kowalska A. Neurol Neurochir Pol. 2004 Nov-Dec;38(6):495-501. Neurol Neurochir Pol. 2004. PMID: 15654674 Review. Polish. - Genetic testing should not be advocated as a diagnostic tool in familial forms of dementia.
Croes EA, Dermaut B, van Der Cammen TJ, van Broeckhoven C, van Duijn CM. Croes EA, et al. Am J Hum Genet. 2000 Oct;67(4):1033-5. doi: 10.1086/303074. Am J Hum Genet. 2000. PMID: 10986048 Free PMC article. No abstract available. - Presenilin 1 mutation in an african american family presenting with atypical Alzheimer dementia.
Rippon GA, Crook R, Baker M, Halvorsen E, Chin S, Hutton M, Houlden H, Hardy J, Lynch T. Rippon GA, et al. Arch Neurol. 2003 Jun;60(6):884-8. doi: 10.1001/archneur.60.6.884. Arch Neurol. 2003. PMID: 12810495 - Presenile because of presenilin: the presenilin genes and early onset Alzheimer's disease.
Haass C. Haass C. Curr Opin Neurol. 1996 Aug;9(4):254-9. Curr Opin Neurol. 1996. PMID: 8858181 Review.
Cited by
- Genetic Testing in Parkinson's Disease.
Pal G, Cook L, Schulze J, Verbrugge J, Alcalay RN, Merello M, Sue CM, Bardien S, Bonifati V, Chung SJ, Foroud T, Gatto E, Hall A, Hattori N, Lynch T, Marder K, Mascalzoni D, Novaković I, Thaler A, Raymond D, Salari M, Shalash A, Suchowersky O, Mencacci NE, Simuni T, Saunders-Pullman R, Klein C. Pal G, et al. Mov Disord. 2023 Aug;38(8):1384-1396. doi: 10.1002/mds.29500. Epub 2023 Jun 27. Mov Disord. 2023. PMID: 37365908 Free PMC article. - Evaluation of an educational conference for persons affected by hereditary frontotemporal degeneration and amyotrophic lateral sclerosis.
Dratch L, Mu W, Wood EM, Morgan B, Massimo L, Clyburn C, Bardakjian T, Grossman M, Irwin DJ, Cousins KAQ. Dratch L, et al. PEC Innov. 2022 Nov 24;2:100108. doi: 10.1016/j.pecinn.2022.100108. eCollection 2023 Dec. PEC Innov. 2022. PMID: 37214502 Free PMC article. - Psychiatric and Psychosocial Characteristics of a Cohort of Spanish Individuals Attending Genetic Counseling Due to Risk for Genetically Conditioned Dementia.
Sobregrau P, Peri JM, Sánchez Del Valle R, Molinuevo JL, Barra B, Pintor L. Sobregrau P, et al. J Alzheimers Dis Rep. 2022 Aug 5;6(1):461-478. doi: 10.3233/ADR-210067. eCollection 2022. J Alzheimers Dis Rep. 2022. PMID: 36186729 Free PMC article. - PSEN1 c.1292C<A Variant and Early-Onset Alzheimer's Disease: A Scoping Review.
Orozco-Barajas M, Oropeza-Ruvalcaba Y, Canales-Aguirre AA, Sánchez-González VJ. Orozco-Barajas M, et al. Front Aging Neurosci. 2022 Jul 22;14:860529. doi: 10.3389/fnagi.2022.860529. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35959289 Free PMC article. - Mindfulness-Based Stress Reduction in Pre-symptomatic Genetic Frontotemporal Dementia: A Pilot Study.
Poos JM, van den Berg E, Papma JM, van der Tholen FC, Seelaar H, Donker Kaat L, Kievit JA, Tibben A, van Swieten JC, Jiskoot LC. Poos JM, et al. Front Psychiatry. 2022 Apr 27;13:864391. doi: 10.3389/fpsyt.2022.864391. eCollection 2022. Front Psychiatry. 2022. PMID: 35573340 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials